Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02274155 · ClinicalTrials.gov registry record · Phase 1
Anti-OX40 Antibody in Head and Neck Cancer Patients
A Phase 1 study, sponsored by Providence Health & Services.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT02274155: Completed Phase 1 study, sponsored by Providence Health & Services.
NCT02274155 is a Phase 1 study that has completed, run by Providence Health & Services. The registered enrollment target is 17 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02274155, a Phase 1 study, has completed, sponsored by Providence Health & Services.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety of the anti-OX40 antibody, MEDI6469, given prior to surgery in patients with advanced head and neck squamous cell carcinoma.
Primary Outcome
Patients will be seen in clinic 7 times over 55 days to identify any possible side effects or complications thought to be related to the study drug to help identify the optimal treatment schedule.
Interventions
- PROCEDURE Surgical Resection
- DRUG Anti-OX40 antibody administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2014-11-12 |
| Est. Completion | 2023-12-21 |
| Phase | Phase 1 |
What the finished NCT02274155 record still lists
NCT02274155 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower).
The record links to 0 conditions, and to 2 interventions - of which Surgical Resection is the first listed.
NCT02274155 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02274155 about?
NCT02274155 is a clinical study titled "Anti-OX40 Antibody in Head and Neck Cancer Patients". The purpose of this study is to test the safety of the anti-OX40 antibody, MEDI6469, given prior to surgery in patients with advanced head and neck squamous cell carcinoma.
What is the current status of trial NCT02274155?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2014-11-12. Estimated completion is 2023-12-21.
What interventions are being tested in trial NCT02274155?
The interventions under investigation include: Surgical Resection (PROCEDURE), Anti-OX40 antibody administration (DRUG).
Who is sponsoring clinical trial NCT02274155?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02274155's enrollment target sits among peer trials
17 1785th of 2000 higher than 215 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI